Table 1.
Sodium glucose cotransporter 2 inhibitors (SGLT2i) trials in type 2 diabetes.
| Trial (Medication) |
Main Outcome HR (95% CI) (p-Value) |
Key Summary |
|---|---|---|
| EMPA-REG OUTCOME [5] (empagliflozin 10 or 25 mg) |
↓ MACE, 0.86 (0.74–0.99) (p = 0.04) ↓ HHF ↓ All cause death |
This was the first SGLT2i trial showing reduction of CV events. |
| CANVAS Program [6,11] (canagliflozin 100 or 300 mg) | ↓ MACE 0.86 (0.75–0.97) (p = 0.02) |
Canagliflozin reduced CV events and HHF. |
| DECLARE-TIMI 58 [8] (dapagliflozin 10 mg) |
↓ CV death or HHF 0.83 (0.73–0.95) (p = 0.005) |
Dapagliflozin reduced CV death and HHF. MACE was not reduced. |
| VERTIS CV [12] (ertugliflozin 5 or 15 mg) |
MACE 0.97 (0.75–1.03) (p < 0.001 for noninferiority) |
Ertugliflozin is non-inferior to placebo in reducing MACE. |
CV, cardiovascular; eGFR, estimated glomerular filtration rate; HHF, heart failure for hospitalization; MACE, major adverse cardiovascular event.